NeuroMetrix, Inc. Names Brad Smith as Chief Financial Officer

    Business Editors/Health/Medical Writers

    WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 8, 2005--NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the design, development and sale of proprietary products used to diagnose neuropathies, announced today that it has named Brad Smith to serve as its Chief Financial Officer, effective February 14, 2005.
    Brad Smith brings over 20 years of experience in the financial management of small and large companies, including over fifteen years of experience managing the financial growth of healthcare and biotechnology companies. In addition, Mr. Smith has been involved in raising over $200 million in public and private equity financing for several biotechnology and medical technology companies.
    Prior to joining NeuroMetrix, Mr. Smith was the Chief Financial Officer and Executive Vice President at Synarc, Inc., a provider of clinical trials services to the pharmaceutical and biotechnology industries. He was responsible for global financial operations, raised private equity financing from several venture capital firms and completed the acquisition of a medical imaging services company. Prior to Synarc he was at PatientKeeper, a company providing healthcare professionals with mobile computing solutions. At PatientKeeper, he was instrumental in raising private funding with venture capital and strategic investors and helping the company launch its initial products. Previously, Mr. Smith served as Chief Financial Officer at Focal, Inc., and led the company through several rounds of private and public equity financing including management of its initial public offering. Prior to Focal, Mr. Smith served as Director of Finance and Treasurer of CytoTherapeutics, where he played a key role in raising capital for two private placements and the company's initial public offering. Previous experience includes financial roles at ImmuCell Corporation, a biotechnology company, Senior Financial Analyst in mergers & acquisitions at Sanders Associates, a division of Lockheed Corp., and Senior Accountant at Coopers & Lybrand, working primarily with emerging growth businesses.
    Brad Smith received his MBA from the Whittemore School at the University of New Hampshire. Mr. Smith received his CPA designation in 1983 and has a Bachelors of Science degree in biology from Tufts University in Boston, MA.
    Shai N. Gozani, M.D., Ph.D, NeuroMetrix's President and CEO said, "We are excited to have Brad join the NeuroMetrix management team. He is an executive with both the intellect and extensive experience to positively impact and contribute to our business. I look forward to working closely with Brad as we continue developing NeuroMetrix into a premier medical device company."
    Brad Smith commented, "NeuroMetrix represents a highly attractive opportunity and I am very excited to be joining Shai and the rest of the talented team at NeuroMetrix."

    About NeuroMetrix

    NeuroMetrix is a medical device company establishing a new standard of care through the design, development and sale of proprietary products used to diagnose neuropathies. Neuropathies are diseases of the peripheral nerves and parts of the spine that frequently are caused by or associated with diabetes, low back pain and carpal tunnel syndrome, as well as other clinical disorders. The NC-stat System, the Company's neuropathy diagnostic system, has been on the market since May 1999 and is presently used in over 2,200 physician's offices, clinics and other health care facilities in the United States. The Company holds issued utility patents covering a number of important aspects of the NC-stat System.

--30--SP/bo*

CONTACT: NeuroMetrix, Inc. Nicholas J. Alessi, 781-890-9989 neurometrix.ir@neurometrix.com

KEYWORD: MASSACHUSETTS INDUSTRY KEYWORD: MEDICAL DEVICES MANAGEMENT CHANGES SOURCE: NeuroMetrix, Inc.

Copyright Business Wire 2005